Lipocine Inc. | Mutual Funds
Mutual Funds that own Lipocine Inc.
Vanguard Total Stock Market Index Fund
471,782
2.22%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
208,893
0.98%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
73,787
0.35%
0
0%
07/31/2018
iShares Core S&P Total US Stock Market ETF
42,598
0.2%
0
0%
09/06/2018
DFA US Core Equity 2 Portfolio
41,781
0.2%
0
0%
04/30/2018
Vanguard Institutional Total Stock Market Index Fund
24,909
0.12%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
20,645
0.1%
0
0%
07/31/2018
DFA US Small Cap Portfolio
19,313
0.09%
0
0%
04/30/2018
DFA US Core Equity 1 Portfolio
19,043
0.09%
0
0%
04/30/2018
DFA US Vector Equity Portfolio
18,258
0.09%
0
0%
04/30/2018
| Address |
675 Arapeen Drive
Salt Lake City Utah 84108
United States
|
|
Employees
|
- |
| Website |
http://www.lipocine.com |
| Updated |
07/08/2019 |
| Lipocine, Inc. is a pharmaceutical company, which engages in the research and development of treatment for use in men's and women's health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded on July 24, 2013 and is headquartered in Salt Lake City, UT. |
